Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23292002 | 0.80 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL30467424 | 0.80 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL21685421 | 0.80 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL15771064 | 0.79 | DGAT1 (0.36) | DGAT1DUTNPC1 | |
| SCHEMBL30729607 | 0.78 | DGAT1 (0.39) | DGAT1DUT | |
| SCHEMBL1291499 | 0.76 | HDAC1 (0.38) | DGAT1DUTNPC1 | |
| SCHEMBL17902171 | 0.76 | DGAT1 (0.36) | DGAT1DUT | |
| SCHEMBL1076270 | 0.75 | DGAT1 (0.39) | DGAT1DUTNPC1 | |
| SCHEMBL25253861 | 0.75 | FGFR1 (0.35) | DGAT1DUT | |
| SCHEMBL98891 | 0.75 | FGFR1 (0.35) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015357-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NEUMORA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024006559-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006559-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015357-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NOD1, CASP1 | DGAT1 2808/4885DUT 4500/4885NPC1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.